Document is current
Any future updates will be listed below
-
Authors
Thorsen, Thor S. https://orcid.org/0000-0002-4301-7342
Kulkarni, Yashraj https://orcid.org/0000-0002-7643-9867
Sykes, David A. https://orcid.org/0000-0002-6606-888X
Bøggild, Andreas https://orcid.org/0000-0003-2130-3521
Drace, Taner
Hompluem, Pattarin
Iliopoulos-Tsoutsouvas, Christos
Nikas, Spyros P. https://orcid.org/0000-0001-5052-5292
Daver, Henrik https://orcid.org/0000-0001-7803-5033
Makriyannis, Alexandros https://orcid.org/0000-0003-3272-3687
Nissen, Poul
Gajhede, Michael https://orcid.org/0000-0001-9864-2287
Veprintsev, Dmitry B. https://orcid.org/0000-0002-3583-5409
Boesen, Thomas
Kastrup, Jette S.
Gloriam, David E. https://orcid.org/0000-0002-4299-7561
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R313-2019-526, R383-2022-306)
Novo Nordisk Fonden (NNF18OC0031226)
Roche (RPF-551)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA009158)
RCUK | Medical Research Council (MR/Y003667/1)
- License Information
-
More Information
Article History
Received: 18 April 2024
Accepted: 30 December 2024
First Online: 8 January 2025
Competing interests
: D.E.G. is a part-time employee and warrant-holder at Kvantify. D.A.S and D.B.V. are both founders and directors of Z7 Biotech Ltd, an early-stage drug discovery CRO. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
